By Natalie Weger
Indivior shares jumped after the pharmaceuticals company raised its full-year revenue guidance and swung to a second-quarter profit.
Shares earlier rose 21% to a fresh 52-week high of $21.01, and were recently trading at $19.47. The stock is now up 57% for the year.
Indivior on Thursday raised its full-year 2025 revenue guidance to between $1.03 billion and $1.08 billion, up from its previous guidance of $955 million to $1.03 billion.
Chief Executive Joe Ciaffoni said the company's Sublocade treatment's net revenue, and its Suboxone film's pricing stability, led the company to raise its guidance.
Indivior swung to a second-quarter profit of $18 million, or 14 cents a share, compared with a loss of $97 million, or 72 cents a share, in the same quarter last year.
Net revenue increased to $302 million, compared with $299 million in last year's comparable quarter. Analysts polled by FactSet expected $241.7 million.
Indivior also raised its outlook for adjusted earnings before interest, taxes, depreciation and amortization to between $275 million and $300 million, up from its previously issued guidance of $220 million to $260 million.
Write to Natalie Weger at natalie.weger@wsj.com
(END) Dow Jones Newswires
July 31, 2025 14:03 ET (18:03 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.